John LaMattina, FORBES CONTRIBUTOR In the summer of 1993, Dr. Paul Changelian, a scientist in Pfizer’s immune suppression group, was looking for a new way to prevent organ transplant rejection. Paul, always on the lookout for new ideas, particularly ones related to suppressing an overactive immune systems (a hallmark of diseases like psoriasis and rheumatoid…

[Read More…]

Innovations: John O’Shea and Arthritis Drug BY ADAM THOMAS You may have seen ads on television for Xeljanz (tofacitinib), a drug used to treat rheumatoid arthritis. Don’t ask me where the name came from. But I can tell you that the drug itself was the brainchild of NIH physician and immunologist John O’Shea. O’Shea, who…

[Read More…]

CHICAGO, IL – September 25, 2015 — SAMDI Tech and Confluence Discovery Technologies are expanding their service offering by entering into a partnership agreement, allowing SAMDI Tech and Confluence Discovery Technologies to mutually promote their respective services. The two companies aim to offer a range of services from drug discovery to preclinical development, combining their…

[Read More…]